• Non ci sono risultati.

WCLC 2015DENVER 2015 - 16TH WORLD CONFERENCE ON LUNG CANCER

N/A
N/A
Protected

Academic year: 2022

Condividi "WCLC 2015DENVER 2015 - 16TH WORLD CONFERENCE ON LUNG CANCER"

Copied!
2
0
0

Testo completo

(1)

BEST OF

WCLC 2015 DENVER 2015 - 16TH WORLD CONFERENCE ON LUNG CANCER

TORINO

14 Settembre FIRENZE

15 Settembre BARI

16 Settembre

Save the date!

(2)

Responsabile Scientifico:

Prof.ssa Silvia Novello

Coordinatori Best of WCLC 2015

Torino Prof. Giorgio Scagliotti (Orbassano) Firenze Dr. Francesco Di Costanzo (Firenze) Bari Dr. Domenico Galetta (Bari) Iscrizione

L’iscrizione agli eventi è gratuita Pre-Iscrizioni e informazioni www.bestofwclc2015.com

Segreteria Organizzativa e Provider

Doc Congress Srl

Via S. Giovanna D’Arco, 47 20099 Sesto S. Giovanni (MI) Tel. +39 02 24.449.248-233 Fax +39 02 24.449.227

[email protected] [email protected]

Gli eventi hanno ricevuto il patrocinio di:

IASLC

International Association for the Study of Lung Cancer

AIOM

Associazione Italiana di Oncologia Medica

AIPO

Associazione Italiana Pneumologi Ospedalieri

SIAPEC

Società Italiana di Anatomia Patologica e Citologia Diagnostica

AIRO

Associazione Italiana di Radioterapia Oncologica

WALCE

Women Against Lung Cancer in Europe

APOT

Associazione Piemontese di Oncologia

“Insieme contro il cancro”

Fondazione

L’evento di Bari ha ricevuto inoltre il patrocinio di:

GOIM

Gruppo Oncologico dell’Italia Meridionale

L’evento di Torino ha ricevuto inoltre il patrocinio di:

Rete Oncologica del Piemonte e della Valle D’Aosta

BEST OF

WCLC 2015

DENVER 2015 - 16TH WORLD CONFERENCE ON LUNG CANCER

Riferimenti

Documenti correlati

Chapter 3 3.1 : Cell free DNA analysis by SiRe® next generation sequencing panel in non small cell lung cancer patients: focus on basal setting ..... Background: In the

Low dose computed tomography (LDCT) is currently the most suitable tool for the early diagnosis of lung cancer as shown by the results of the NLST, NELSON and MILD studies that

Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study..

describe hospital costs due to lung cancer care from diagnosis until death or end of the study follow-up, in a cohort of incident cases, by using administrative data..

The European Prospective Investigation into Cancer and Nutrition (EPIC) was carried out with financial support of the ‘Europe Against Cancer’ Programme of the European

Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor- Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases. Int J Radiat Oncol

Immune checkpoint inhibitors (ICIs) directed against programmed cell death protein 1(PD-1) and its ligand (PD-L1) have rapidly changed non-small cell lung cancer (NSCLC)

The tetrahydroacridine derivatives with iodobenzoic acid moiety 1a–1i were tested in vitro by MTT assay against two human cancer cell lines—lung adenocarcinoma A549 and